Patent intelligence · US
US 12263173
PLK1 inhibitor in combination with anti-angiogenics for treating metastatic cancer
PLK1 inhibitor in combination with anti-angiogenics for treating metastatic cancer
Patent details — US 12263173
- Jurisdiction
- US
- Status
- granted
- Grant date
- Apr 1, 2025
- Expiration
- Mar 27, 2045
- Applicant
- Cardiff Oncology, Inc.
- Claims
- 20
- CPC classes
- A61K, A61K2039/505, A61K2039/545, A61K2300/00
Quick answer
US 12263173 (PLK1 inhibitor in combination with anti-angiogenics for treating metastatic cancer) is held by Cardiff Oncology, Inc.. Status: granted. Granted Apr 1, 2025. Expires Mar 27, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Cardiff Oncology, Inc.
- Grant date
- Expiration
- Claims
- 20
- CPC classes
- A61K, A61K2039/505, A61K2039/545, A61K2300/00, A61K31/437, A61K31/4745
More from Cardiff Oncology, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12383540
Compounds that modulates AMPA receptor function
granted -
US 12318418
Modified adenoviruses
granted -
US 12144813
PLK1 inhibitor in combination with anti-angiogenics for treating metastatic cancer
granted -
US 12053513
Cancer-specific T-cell receptors
granted -
US 11957677
Cancer treatment using FGFR inhibitors and PLK1 inhibitors
granted -
US 11850264
Gamma delta T-cell receptor and its ligand
granted -
US 11725039
α/β t-cell receptor and methods of using it
granted
Frequently asked questions
What is US patent 12263173?
US 12263173 (PLK1 inhibitor in combination with anti-angiogenics for treating metastatic cancer) is held by Cardiff Oncology, Inc.. Status: granted. Granted Apr 1, 2025. Expires Mar 27, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12263173?
Cardiff Oncology, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 69 pharmaceutical patents for this assignee.
When does US 12263173 expire?
Our index shows an expiration date of Mar 27, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.